Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.
90% to 100% of study participants achieved complete or partial responses to treatment.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Microbiome triggers top killer after bone marrow transplant — and there’s a potential way to stop it
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
September is the awareness period of a whopping total of seven cancers. Seven!
Trying to mimic the “Berlin Patient” cure, researchers edited the CCR5 gene in the immune stem cells of a man with leukemia and HIV.
I really have no idea how one should properly celebrate the month of one’s cancer.
Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
The trial is testing an experimental drug that targets one of the malignant immune cells that are a hallmark of the disease.
The researchers are now designing a first-in-human clinical trial to test the effectiveness of this approach in patients.
But new vaccines hold promise for prevention.
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.